DX600

O=C(C1([H])N(CCC1)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(C2([H])N(CCC2)C([C@@H](NC([C@H](CSSC[C@H](NC([C@@H](NC([C@@H](NC3=O)CC4=CNC5=CC=CC=C45)=O)CCCCN)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC6=CC=C(C=C6)O)C(N7[C@@H](CCC7)C(N[C@@H](CC(O)=O)C(N8[C@@H](CCC8)C(N[C@@H](CCC(O)=O)C(NCC(NCC(NCC(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)NC([C@@H](NC([C@H](CO)NC([C@@H](NC([C@H](CC(O)=O)NC(CNC(C)=O)=O)=O)CC9=CC=C(C=C9)O)=O)=O)CC%10=CN=CN%10)=O)=O)CO)=O)=O)CC(C)C)=O)CCCNC(N)=N)=O)CC%11=CC=C(C=C%11)O)=O)CC%12=CC=C(C=C%12)O)=O)N[C@H]3CC%13=CNC%14=CC=CC=C%13%14

[1]Liao K, et al. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2) .J Immunol Methods. 2013 Mar 29;389 (1-2) :52-60.|[2]Yousif MH, et al. Characterization of Angiotensin- (1-7) effects on the cardiovascular system in an experimental model of type-1 diabetes. Pharmacol Res. 2012 Sep;66 (3) :269-75.|[3] Svilenov HL, et al. Extrinsic stabilization of antiviral ACE2-Fc fusion proteins targeting SARS-CoV-2. Commun Biol. 2023 Apr 8;6 (1) :386.|[4]Joshi S, et al. Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells. Eur J Pharmacol. 2016 Mar 5;774:25-33.|[5]Fraga-Silva RA, et al. ACE2 activation promotes antithrombotic activity. Mol Med. 2010 May-Jun;16 (5-6) :210-5.